Paper · 36498669
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 145
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18355325 | Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. | Diabetes Obes Metab | 2008 | https://conductscience.org/library/papers/18355325 | PubMed |
| 2 | 24622369 | Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Diabetes Endocrinol | 2013 | https://conductscience.org/library/papers/24622369 | PubMed |
| 3 | 15549021 | Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. | MMWR Morb Mortal Wkly Rep | 2004 | https://conductscience.org/library/papers/15549021 | PubMed |
| 4 | 17223217 | Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. | Diabetes Res Clin Pract | 2007 | https://conductscience.org/library/papers/17223217 | PubMed |
| 5 | 18355324 | Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. | Diabetes Obes Metab | 2008 | https://conductscience.org/library/papers/18355324 | PubMed |
| 6 | 27171508 | Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. | J Diabetes | 2017 | https://conductscience.org/library/papers/27171508 | PubMed |
| 7 | 23279307 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. | Diabetes Obes Metab | 2013 | https://conductscience.org/library/papers/23279307 | PubMed |
| 8 | 20332588 | Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. | Endocr J | 2010 | https://conductscience.org/library/papers/20332588 | PubMed |
| 9 | 16189256 | Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. | J Clin Endocrinol Metab | 2005 | https://conductscience.org/library/papers/16189256 | PubMed |
| 10 | 21146883 | Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. | Diabetes Res Clin Pract | 2011 | https://conductscience.org/library/papers/21146883 | PubMed |
| 11 | 24400655 | Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. | Diabetes Obes Metab | 2014 | https://conductscience.org/library/papers/24400655 | PubMed |
| 12 | 27088241 | Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/27088241 | PubMed |
| 13 | 18201212 | Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. | Diabet Med | 2008 | https://conductscience.org/library/papers/18201212 | PubMed |
| 14 | 16823726 | Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. | Horm Metab Res | 2006 | https://conductscience.org/library/papers/16823726 | PubMed |
| 15 | 25238025 | Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. | Diabetes Obes Metab | 2015 | https://conductscience.org/library/papers/25238025 | PubMed |
| 16 | 20334663 | Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. | Cardiovasc Diabetol | 2010 | https://conductscience.org/library/papers/20334663 | PubMed |
| 17 | 15154941 | An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. | Diabet Med | 2004 | https://conductscience.org/library/papers/15154941 | PubMed |
| 18 | 12682825 | Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. | Acta Diabetol | 2003 | https://conductscience.org/library/papers/12682825 | PubMed |
| 19 | 19622552 | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. | BMJ | 2009 | https://conductscience.org/library/papers/19622552 | PubMed |
| 20 | 18495285 | Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. | Diabetes Res Clin Pract | 2008 | https://conductscience.org/library/papers/18495285 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36498669/references